Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Juvederm Ultra XC
- Development stage
- Unknown
- Lead developer
- Allergan
- Modality
- Small Molecules
- Administration
- Intradermal, Submucosal
01
Overview
Juvederm Ultra XC is an injectable hyaluronic acid-based dermal filler formulated with lidocaine to enhance patient comfort during administration. Developed by Allergan (now part of AbbVie), it consists of cross-linked hyaluronic acid (24 mg/mL) produced via bacterial fermentation from *Streptococcus equi* and cross-linked using 1,4-butanediol diglycidyl ether (BDDE). The product is FDA-approved for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, and for lip augmentation in adults over the age of 21. Its mechanism of action involves the physical restoration of volume to the dermis or submucosal tissue, where the hyaluronic acid binds water to provide structural support and hydration. In clinical research contexts, such as those led by DeNova Research, it has been specifically evaluated for lip augmentation in diverse populations, including women with Fitzpatrick skin types V and VI.
- Brand names
- Juvederm Ultra XC
- Other names
- Juvederm Ultra XC-DeNova ResearchJuvederm Ultra XC filler
02
Targets
SCN5A (Sodium channel protein type 5 subunit alpha)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)SCN2A (Voltage-gated sodium channel protein type 2 subunit alpha)
Beyond the preview
Go deeper on Juvederm Ultra XC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Juvederm Ultra XC.